<DOC>
	<DOCNO>NCT01477073</DOCNO>
	<brief_summary>The aim current study pharmacokinetic pharmacodynamic characterization multiple dose administration FSH-GEX™ healthy pituitary-suppressed female volunteer , comparison two market comparator product .</brief_summary>
	<brief_title>Multiple Dose FSH-GEX ( TM ) Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Infertility , Female</mesh_term>
	<criteria>1 . Female subject 1840 year age screening . 2 . Subjects must good health determine medical gynecological history , physical gynecological examination , vital sign , body measurement , electrocardiogram , laboratory test 3 . Subjects must willing use additional nonhormonal contraception 4 . Subjects must use combined oral contraceptive , combine contraceptive vaginal ring combine contraceptive patch 5 . Vital sign within follow range : systolic blood pressure 90140 mmHg , diastolic blood pressure 5090 mmHg , pulse rate 40 100 bpm 6 . Subjects must body weight minimally 50.0 kg BMI 18.0 29.9 kg/m2 7 . Able provide write informed consent prior study participation . 8 . Able communicate well investigator understand comply requirement study . 1 . Smokers 5 cigarette per day . 2 . Average daily intake 3 unit alcohol per day ( 1 unit equal 250 mL beer , 125 mL wine 25 mL spirit ) average weekly intake 21 unit alcohol . 3 . Use prescription drug OTC medication screen endofstudy visit , without prior approval investigator . Paracetamol® acceptable without prior approval . 4 . Any drug may reduce effectiveness COC screen endofstudy visit 5 . Administration investigational product use investigational device within 30 day prior Screening . 6 . Donation loss 500 mL blood within 90 day prior first dose FSHGEX ( TM ) . 7 . History acute chronic bronchospastic disease 8 . History allergy drug , seafood , nut , egg , waspstings ; history atopic allergy . A known hypersensitivity study drug . 9 . Any surgical medical condition might alter absorption , distribution , metabolism , excretion drug may jeopardize subject case participation study . 10 . History presence malignancy . 11 . Determined suspected pregnancy . 12 . Breast feeding woman . 13 . History ( current ) endocrine abnormalities 14 . Contraindication use oral contraceptive 15 . Contraindication use follitropin alfa , folliclestimulating hormone ( FSH ) excipients ( hypersensitivity follitropin alfa , FSH excipients ; tumor hypothalamus pituitary gland ; ovarian enlargement cyst due polycystic ovarian disease ; gynecological bleed unknown origin ; ovarian , uterine , mammary carcinoma ) . 16 . Porphyria family history porphyria . 17 . History ovarian surgery . 18 . Any ovarian abdominal abnormality would interfere adequate ultrasound investigation . 19 . An abnormal cervical smear 20 . History presence immunecompromising disease , positive human immunodeficiency virus ( HIV ) test result past screen visit . 21 . History Hepatitis B C , positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C test result screen visit . 22 . History drug alcohol abuse within 12 month prior screen visit evidence abuse 23 . Planned surgery hospitalization period study . 24 . Concurrent participation participation within 30 day screen another clinical trial , participation 3 clinical study within 12 month , prior expect date enrolment study previous participation 104676CS0160 ( FSHGEXTM ) study . 25 . Injection one dose depot contraceptive drug /drug combination ≤10 month prior screen .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>in-vitro fertilization</keyword>
	<keyword>reproductive disorder</keyword>
</DOC>